PolyMedix to present data on its heptagonist compounds

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

The data will be presented in a poster on December 8, 2009, Abstract 2092, titled: “Novel Antagonists for Low Molecular Weight Heparin and Heparin-Like Drugs” Lead author and investigator is Dr. Walter Jeske, of the Cardiovascular Institute of Loyola University Medical Center, Maywood, Illinois, where the studies were conducted. The poster describes the activities of several PolyMedix heptagonist compounds and their abilities to reverse the action of low molecular weight heparin and heparin-like drugs, enoxaparin and fondaparinux.

PolyMedix’s lead heptagonist compound is PMX-60056, currently in Phase 1 clinical development. On October 27, 2009 PolyMedix announced the completion of a successful Phase 1B pilot proof of concept human clinical study with PMX-60056. The results of that study demonstrated that PMX-60056 completely reversed the anticoagulant effects of heparin and normalized blood clotting time in human subjects in less than 10 minutes, and that no serious adverse events occurred during the study.